Please enable Javascript
Melissa Badamo
Articles by Melissa Badamo
What Is the Role of Selinexor on Myeloma Bone Marrow Samples?
Melissa Badamo
Myeloma
|
December 9, 2023
The results suggest a possible treatment strategy of selinexor followed by immunotherapy.
Read More
Tasquinimod Treatment Improves Survival in Murine MPN-AML Models
Melissa Badamo
Myeloproliferative Neoplasms
|
December 9, 2023
Tasquinimod inhibited interaction of A9, a protein associated with poor prognosis.
Read More
Survey Examines Global Access to Myeloma Therapies
Melissa Badamo
Myeloma
|
December 9, 2023
The survey examined global access to 14 chemoimmunotherapy options and autologous stem cell transplant (ASCT).
Read More
BCL-xL Degrader DT2216 Is Effective in JAK2 Mutant AML Post-MPN Models
Melissa Badamo
Myeloproliferative Neoplasms
|
December 9, 2023
DT2216 alone was effective, but exhibited a slightly greater cell viability reduction when combined with other therapies.
Read More
Liso-cel Effective in Patients with Relapsed or Refractory MCL with High-risk Disease Features
Melissa Badamo
Mantle Cell Lymphoma
|
December 6, 2023
Those high-risk disease features include high proliferation index, TP53 mutation, blastoid morphology, and CNS lymphoma.
Read More
DS-1594b Plus Venetoclax Is Effective in NPM1-Mutated AML
Melissa Badamo
Acute Myeloid Leukemia
|
December 6, 2023
The study tested the combination therapy in a patient-derived xenograft (PDX) model of NPM1-mutated AML.
Read More
Liso-cel Has Favorable Benefit in Patients with LBCL
Melissa Badamo
Aggressive B-Cell Lymphoma
|
December 5, 2023
One-time liso-cel infusion demonstrated durable responses in R/R LBCL.
Read More
FDA Grants Accelerated Approval to Pirtobrutinib for CLL
Melissa Badamo
Chronic Lymphocytic Leukemia
|
December 5, 2023
The accelerated approval was based on efficacy results from the BRUIN trial.
Read More
Follow-up Analysis of Tirabrutinib in Patients with PCNSL
Melissa Badamo
Indolent B-Cell Lymphoma
|
December 4, 2023
Researchers assessed the number of patients who received subsequent treatment after tirabrutinib discontinuation.
Read More
Combination Treatment Is Tolerable in Adults with BCR-ABL1-Positive ALL, Blast Phase CML
Melissa Badamo
Acute Lymphoblastic Leukemia
|
December 4, 2023
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
Read More
Blinatumomab Provides Clinical Benefit for Patients with Ph- B-ALL
Melissa Badamo
Acute Lymphoblastic Leukemia
|
December 4, 2023
93% of patients became measurable residual disease (MRD) negative after the first cycle of blinatumomab.
Read More
TP-3654 Monotherapy Well-tolerated in Relapsed or Refractory Myelofibrosis
Melissa Badamo
Myelofibrosis
|
November 30, 2023
Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.
Read More
Do High Molecular Risk Mutations Increase Leukemia Risk in Myelofibrosis?
Melissa Badamo
Myelofibrosis
|
December 1, 2023
The multicenter trial studied genetic mutations across three cohorts.
Read More
Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera
Melissa Badamo
Polycythemia Vera
|
November 28, 2023
CR rates were comparable in both treatment groups, but OS was superior in the ruxolitinib group.
Read More
Lower Dose CPX-351 Is Safe in Patients with HR-MDS
Melissa Badamo
Myelodysplastic Syndromes
|
November 27, 2023
The study determined the maximum tolerated dose of CPX-351, but further studies are needed to evaluate its activity.
Read More
Molecular Perturbations in Bone Marrow Cells Could Promote MDS
Melissa Badamo
Myelodysplastic Syndromes
|
November 27, 2023
The study evaluated mesenchymal cell molecular features and sought modifications that might affect MDS.
Read More
Selinexor Plus Ruxolitinib Well Tolerated in JAKi-Naïve Patients with Myelofibrosis
Melissa Badamo
Myelofibrosis
|
November 17, 2023
Researchers also observed potential disease modification via rapid stabilization of platelets and stable hemoglobin levels.
Read More
Pelabresib Plus Ruxolitinib Is a Promising Treatment Regimen for Myelofibrosis
Melissa Badamo
Myelofibrosis
|
November 16, 2023
The trial is based on “compelling data” from arm III of the ongoing phase II MANIFEST study.
Read More
Patients, APPs Wish for Increased Educational Resources Surrounding MM
Melissa Badamo
Myeloma
|
November 15, 2023
Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.
Read More
Triple Therapy Treatment Is Safe, Effective in APL
Melissa Badamo
Acute Myeloid Leukemia
|
November 14, 2023
Early deaths remain a barrier against understanding a cure-for-all.
Read More
Load More